Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06334783
Status:
RECRUITING
Last Update Posted:
2024-03-28
First Post:
2024-03-21
Brief Title:
TIL for Patients With Advanced Solid Tumor
Sponsor:
Hervor Therapeutics
Organization:
Hervor Therapeutics
Study Overview
Official Title:
Tumor Infiltrating Lymphocyte TIL Therapy for the Treatment of Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Background
Tumor-infiltrating lymphocyte TIL therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors culturing and amplifying them in vitro and then infusing back to patients
TIL therapy has shown strong efficacy for the treatment of solid tumors and has achieved high objective response rates in multiple cancers such as melanoma NSCLC and cervical cancer
Objective
To evaluate the safety and efficacy of TIL for the patients with advanced solid tumor
Eligibility
Adults aging 18-75 with advanced solid tumor
Design
1 Patients will undergo screening tests including imaging procedures heart and lung tests and lab tests
2 Freshly resected patient tumors were dissected by the surgeon
3 TIL cells were isolated from the patients tumor tissue then cultured in vitro activated and expanded
4 At last TIL cells will be re-infused into the patients
Tumor-infiltrating lymphocyte TIL therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors culturing and amplifying them in vitro and then infusing back to patients
TIL therapy has shown strong efficacy for the treatment of solid tumors and has achieved high objective response rates in multiple cancers such as melanoma NSCLC and cervical cancer
Objective
To evaluate the safety and efficacy of TIL for the patients with advanced solid tumor
Eligibility
Adults aging 18-75 with advanced solid tumor
Design
1 Patients will undergo screening tests including imaging procedures heart and lung tests and lab tests
2 Freshly resected patient tumors were dissected by the surgeon
3 TIL cells were isolated from the patients tumor tissue then cultured in vitro activated and expanded
4 At last TIL cells will be re-infused into the patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None